{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal stem Bronchopulmonary Dysplasia",
            "NStudiesAvail": 430108,
            "NStudiesFound": 21,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 21,
            "FieldList": [
                  "ResultsFirstSubmitDate",
                  "ResultsFirstSubmitQCDate",
                  "RetractionPMID",
                  "RetractionSource",
                  "SamplingMethod",
                  "SecondaryId",
                  "SecondaryIdDomain",
                  "SecondaryIdLink",
                  "SecondaryIdType",
                  "SecondaryOutcomeDescription",
                  "SecondaryOutcomeMeasure",
                  "SecondaryOutcomeTimeFrame",
                  "SeeAlsoLinkLabel",
                  "SeeAlsoLinkURL",
                  "SeriousEventAssessmentType",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "To evaluate the safety of human umbilical cord -derived mesenchymal stem cells for moderate and severe bronchopulmonary dysplasia. Blood pressure is measured by electronic sphygmomanometer .",
                              "To evaluate the safety of human umbilical cord -derived mesenchymal stem cells for moderate and severe bronchopulmonary dysplasia."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Changes of blood pressure in participants",
                              "Changes of heart rate in participants"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "24 hours after administration",
                              "24 hours after administration"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03601416"
                        ]
                  },
                  {
                        "Rank": 2,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "To evaluate the safety and efficacy of human umbilical cord -derived mesenchymal stem cells for BPD.",
                              "To evaluate the safety of human umbilical cord -derived mesenchymal stem cells for BPD.",
                              "To evaluate the safety of human umbilical cord -derived mesenchymal stem cells for BPD. Blood pressure is measured by electronic sphygmomanometer .",
                              "To evaluate the safety of human umbilical cord -derived mesenchymal stem cells for BPD.",
                              "To evaluate the safety of human umbilical cord -derived mesenchymal stem cells for BPD.",
                              "To evaluate the safety of human umbilical cord -derived mesenchymal stem cells for BPD.",
                              "To evaluate the safety and efficacy of human umbilical cord -derived mesenchymal stem cells for BPD."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Changes of high-resolution chest CT in participants",
                              "Changes of temperature in participants",
                              "Changes of blood pressure in participants",
                              "Changes of heart rate in participants",
                              "Changes of respiratory rate in participants",
                              "Changes of oxygen saturation in participants",
                              "Growth velocity (Z-score) in participants"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "within 2 years after administration",
                              "3 days after administration",
                              "3 days after administration",
                              "3 days after administration",
                              "3 days after administration",
                              "3 days after administration",
                              "within 2 years after administration"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03558334"
                        ]
                  },
                  {
                        "Rank": 3,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Temporal profiles of the fraction of inspiration oxygen 7 days after transplantation, the tolerable required oxygen \uff0cwhich is the minimum fraction of inspiration oxygen in which the participants has a stable SpO2 (90%-95%), measured in %",
                              "The duration from transplantation to weaning from ventilator",
                              "percentage of participants with severe BPD ,diagnosed at 36 weeks PMA",
                              "Percentage of participants who survived up to 36 weeks PMA",
                              "Temporal profiles of temperature",
                              "Temporal profiles of heart rate",
                              "Temporal profiles of respiratory rate",
                              "Duration of CPAP treatment",
                              "Percentage of participants treated with steroids for weaning from ventilator",
                              "percentile for body weight, height, and head circumference",
                              "BAL were collected 7 days after transplantation for cytokine (IL-6\uff0cIL-8\uff0cTNF-\u03b1\uff0cTGF-\u03b2,VEGF,HGF) level examination, measured in pg/ml",
                              "A chest X-ray was performed in participants before and after transplantation. The severity of BPD (mild\uff0cmoderate\uff0csevere) was assessed by a single radiographic doctor who is blind about randomization"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Oxygen requirement 7 days after transplantation",
                              "Duration of ventilator dependence",
                              "Incidence of severe BPD",
                              "Survival rate",
                              "Temperature",
                              "Heart rate",
                              "Respiratory rate",
                              "Duration of CPAP treatment",
                              "Percentage of participants treated with steroids for weaning from ventilator",
                              "Growth velocity (Z-score)",
                              "bronohoalveolar lavage (BAL) cytokine level",
                              "The severity of BPD in X-ray patterns"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "7 days",
                              "up to 36 weeks PMA",
                              "up to 36 weeks PMA",
                              "up to 36 weeks PMA",
                              "3 days",
                              "3 days",
                              "3 days",
                              "up to 36 weeks PMA",
                              "up to 36 weeks PMA",
                              "up to 36 weeks PMA",
                              "7 days",
                              "7 days"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03645525"
                        ]
                  },
                  {
                        "Rank": 4,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Changes of the lung fibrosis on chest CT at 6 months compared with baseline"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "The lung fibrosis"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "at 6 months post treatment"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04062136"
                        ]
                  },
                  {
                        "Rank": 5,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "biomarkers will be measured in pg/ml",
                              "Flattening of the interventricular septum will be the main parameter (tipe I, I-II, II, II-III OR III)",
                              "Diagnosed at 36 weeks of postmenstrual age"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Biomarker analysis (IL-1beta, IL-6, IP-10, INF-gamma, TGF beta, NLRP3, RAGE, HMGB1, VEGFA, GREMLIN1, sVEGFR1, IGF, ENDOTHELIN-1, SMPD-1, SP-D, SMPD3.",
                              "Changes in the echocardiographic parameters related with PH and preterm birth, in patients treated with MSC (Number of participants with echocardiographic adverse events)",
                              "Incidence of BPD and PH in very low birth weight babies treated with MSC"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "24 months",
                              "24 months",
                              "24 months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02443961"
                        ]
                  },
                  {
                        "Rank": 6,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Rate of Survival",
                              "Incidence of Tumorigenicity",
                              "Growth measured by Z-score",
                              "Number of neurological developmental delay",
                              "Number of blindness and deafness"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "within two years",
                              "within two years",
                              "within two years",
                              "within two years",
                              "within two years"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03873506"
                        ]
                  },
                  {
                        "Rank": 7,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03683953"
                        ]
                  },
                  {
                        "Rank": 8,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The severity score of BPD ranging from 0 to 6 on the serial chest radiographs will be graded by a single radiologist, without knowledge of the infant's identity or clinical course, using the roentgenographic severity scoring system."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "The severity score of BPD ranging from 0 to 6 on the serial chest radiographs"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "6 months to 1 year"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01207869"
                        ]
                  },
                  {
                        "Rank": 9,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "scores of Bayley Scales of Infant Development at 2 months old and 2 years old"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Bayley Scales of Infant Development"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "30 months after birth"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03378063"
                        ]
                  },
                  {
                        "Rank": 10,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "To evaluate the efficacy of hUC-MSCs to prevent preterm infants at high risk of BPD from developing BPD",
                              "To evaluate the safety and efficacy of human umbilical cord -derived mesenchymal stem cells for BPDmesenchymal stem cells for BPD.",
                              "To evaluate the safety of human umbilical cord -derived mesenchymal stem cells for BPD.mesenchymal stem cells for BPD.",
                              "To evaluate the safety of human umbilical cord -derived mesenchymal stem cells for BPD. Blood pressure is measured by electronic sphygmomanometer.",
                              "To evaluate the safety of human umbilical cord -derived mesenchymal stem cells for BPD.",
                              "To evaluate the safety of human umbilical cord -derived mesenchymal stem cells for BPD."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "The incidence and severity of BPD defined by the National Institutes of Child Health and Human Development (NICHD) workshop.",
                              "Changes of high-resolution chest CT in participants",
                              "Changes of temperature in participants",
                              "Changes of blood pressure in participants",
                              "Changes of respiratory rate in participants",
                              "Changes of oxygen saturation in participants"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "at the corrected gestational age of 36 weeks",
                              "within 2 years after administration",
                              "3 days after administration",
                              "3 days after administration",
                              "3 days after administration",
                              "3 days after administration"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03774537"
                        ]
                  },
                  {
                        "Rank": 11,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The percentage of subjects who died from any cause during the study.",
                              "Changes from baseline of the oxygen saturation.",
                              "Changes from baseline to 3 months of chest x-ray findings in participants before and after administration.",
                              "Changes from baseline of inflammatory markers (pg/ml) .",
                              "Comparison of the incidence and severity of preterm children's complications in participants before and after administration.",
                              "The number of days of intubation, or where ventilator or oxygen therapy.",
                              "Incidence of moderate/severe BPD or death at 36 weeks postmenstrual age (PMA)."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "The percentage of subjects who died from any cause during the study.",
                              "Changes of the oxygen saturation.",
                              "Changes of chest x-ray findings in participants before and after administration.",
                              "Changes of inflammatory markers (pg/ml) before and after administration.",
                              "Comparison of the incidence and severity of preterm children's complications in participants before and after administration.",
                              "The number of days of intubation, or where ventilator or oxygen therapy.",
                              "Incidence of moderate/severe BPD or death at 36 weeks postmenstrual age (PMA)."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "3 months from the day of administration",
                              "3 months from the day of administration",
                              "3 months from the day of administration",
                              "3 days and 7 days after administration",
                              "3 months from the day of administration",
                              "3 months from the day of administration",
                              "36 weeks postmenstrual age (PMA)"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03631420"
                        ]
                  },
                  {
                        "Rank": 12,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Number of participants with adverse reactions between 84 days after treatment and 20 months of corrected age",
                              "Incidence of moderate/severe BPD or death at 36 weeks postmenstrual age (PMA)",
                              "Hospital Re-admission between 84 days after treatment until 20 months of corrected age",
                              "Bayley Scales of Infant and Toddler Development between 84 days after treatment until 20 months of corrected age"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Between 84 days after treatment and 20 months of corrected age",
                              "36 weeks PMA",
                              "Between 84 days after treatment and 20 months of corrected age",
                              "Between 84 days after treatment and 20 months of corrected age"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02381366"
                        ]
                  },
                  {
                        "Rank": 13,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Incidence of BPD at 36 Week's postmenstrual age (PMA)and 28 week's PMA Survival rate at 28 days after birth and 36 week's PMA"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Incidence of BPD at 36 Week's postmenstrual age"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "36 week's postmenstrual age"
                        ],
                        "SeeAlsoLinkLabel": [
                              "[Journal of Pediatrics] Mesenchymal Stem Cells for Bronchopulmonary Dysplasia: Phase 1 Dose-Escalation Clinical Trial"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://www.jpeds.com/article/S0022-3476(13)01536-9/abstract"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01297205"
                        ]
                  },
                  {
                        "Rank": 14,
                        "ResultsFirstSubmitDate": [
                              "August 24, 2021"
                        ],
                        "ResultsFirstSubmitQCDate": [
                              "September 15, 2021"
                        ],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [
                              "Systematic Assessment"
                        ],
                        "NCTId": [
                              "NCT03857841"
                        ]
                  },
                  {
                        "Rank": 15,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Intubation duration",
                              "Incidence of BPD",
                              "Survival rate",
                              "Duration of ventilator dependence",
                              "Duration of CPAP treatment",
                              "Postnatal steroid use (%) for the purpose of ventilator weaning",
                              "Cumulative duration of oxygen use",
                              "Incidence of Retinopathy of Prematurity (ROP) of Grade III or more",
                              "Retinopathy of Prematurity (ROP) that require treatment with avastin or laser",
                              "Growth velocity (Z-score)",
                              "Length of stay prior to the first discharge from the hospital",
                              "Incidence of adverse events",
                              "Clinically significant laboratory findings",
                              "Incidence of pneumothorax that require intubation",
                              "Incidence of moderate to severe pulmonary hemorrhage",
                              "Incidence of intraventricular hemorrhage of grade 3 or more"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "36 weeks PMA",
                              "28-days since birth",
                              "28-days since birth, 36 weeks PMA, and termination of the trial",
                              "Week 24",
                              "Week 24",
                              "Week 24",
                              "Week 24",
                              "Week 24",
                              "Week 24",
                              "Week 24",
                              "duration of the hospital stay, an expected average of approximately 3 months since birth",
                              "Week 24",
                              "Week 24",
                              "Week 24",
                              "Week 24",
                              "Week 24"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Related Info"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://clinicaltrials.gov/ct2/show/NCT01297205?term=medipost&rank=2"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01828957"
                        ]
                  },
                  {
                        "Rank": 16,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [
                              "Non-Probability Sample"
                        ],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Bayely test results of the 9 subjects who were treated with Pneumostem\u00ae during the early part of the Phase I study.\n\nThe results of Brain MRI study performed at corrected age of 18-24 months.",
                              "Body weight, Head circumference, Height : growth percentile"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Neurological development test outcome from the subjects who were treated with Pneumostem\u00ae, compared with the patients who suffered from the same conditions but not treated with Pneumostem\u00ae",
                              "Growth"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "at corrected age of 10 months (\u00b12 months) and 21 months (\u00b13 months)",
                              "Corrected gestational age of 4-6months, 8-12months, 18-24months"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Safety and Efficacy Evaluation of PNEUMOSTEM\u00ae Treatment in Premature Infants With Bronchopulmonary Dysplasia"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://clinicaltrials.gov/ct2/show/NCT01297205?term=pneumostem&rank=1"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01632475"
                        ]
                  },
                  {
                        "Rank": 17,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "check whether patient is alive or dead at evaluation time point",
                              "Growth measured by Z-score",
                              "Neurological developmental status on Korean Developmental Screening Test for infants and children(K-DST)",
                              "Deafness: audiometry /Blindness: examination of extraocular muscle, fundus photography, optical biometry",
                              "Scale: cognitive, motor, language, social-emotional, adaptive behavior",
                              "Gross Motor Function Classification System for Cerebral Palsy",
                              "Number of adverse events",
                              "Total number of admissions to Emergency Room (ER) and number of admission to Emergency Room (ER) due to respiratory infection at each evaluation time point",
                              "whether or not, the patient is receiving medical treatment(use of oxygen, steroid, or bronchodilator, diuretics, Sildenafil) and if receiving treatment, the duration of the treatment at each evaluation time point"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Mortality",
                              "Growth measured by Z-score",
                              "Neurological developmental status: Korean Developmental Screening Test for infants and children(K-DST)",
                              "Deafness or Blindness",
                              "Bayley Scales of Infant and Toddler Development (Third Edition)",
                              "Gross Motor Function Classification System for Cerebral Palsy",
                              "Number of adverse events",
                              "Number of admissions to Emergency Room (ER)",
                              "Medical treatment records"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "6, 12, 18, 24 months corrected age, 36, 48, and 60 months after birth",
                              "6, 12, 18, 24 months corrected age, 36, 48, and 60 months after birth",
                              "6, 12, 18, 24 months corrected age,36, 48, and 60 months after birth",
                              "24 months corrected age",
                              "18~24months corrected age, 36~42months after birth",
                              "24 months corrected age",
                              "6, 12, 18, 24 months corrected age,36, 48, and 60 months after birth",
                              "6, 12, 18, 24months corrected age, 36, 39, 42, 45, 48, 51, 54, 57 and 60 months after birth",
                              "6, 12, 18, 24months corrected age, 36, 39, 42, 45, 48, 51, 54, 57 and 60 months after birth"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04003857"
                        ]
                  },
                  {
                        "Rank": 18,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Total number of admissions to Emergency Room and number of admissions to Emergency Room due to resiratory problems"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Whether the subject is receiving medical treatments and if so, duration of the treatment (use of oxygen, steroid, or brochodilator)",
                              "Number of admissions to Emergency Room",
                              "Survival",
                              "Growth measured by Z-score",
                              "Neurological developmental status on K-ASQ, Bayley Scale, Gross Motor Function Classification System (GMFCS) for Cerebral Palsy",
                              "Deafness or Blindness",
                              "Number of adverse events",
                              "Significant changes in vital signs",
                              "Significant changes in physical exam"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "6, 12, 18, 24, 36, 48, and 60 months, corrected age",
                              "6, 12, 18, 24, 36, 48, and 60 months, corrected age",
                              "6, 12, 18, 24, 36, 48, and 60 months, corrected age",
                              "6, 12, 18, 24, 36, 48, and 60 months, corrected age",
                              "24 months, corrected age",
                              "24 months, corrected age",
                              "6, 12, 24,36, 48, and 60 months, corrected age",
                              "6, 12, 24, 36, 48, and 60 months, corrected age",
                              "6, 12, 24, 36, 48, and 60 months, corrected age"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01897987"
                        ]
                  },
                  {
                        "Rank": 19,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [
                              "Non-Probability Sample"
                        ],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "hospital readmission rates and length of stay\nwhether medical interventions such as oxygen, steroid, or bronchodilator therapy was done and duration of the therapy\nFrequency of Emergency Room visit (total number of visits/ number of visits due to respiratory illnesses)",
                              "weight\nheight\nhead circumference\npercentile",
                              "K-ASQ (Korean Ages and Stages Questionnaires),\nBayley test (BSID III)"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Respiratory outcomes",
                              "Survival",
                              "Z-score",
                              "Potential neurological development test outcomes"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "60 months (corrected age)",
                              "60 months (corrected age)",
                              "60 months (corrected age)",
                              "60 months (corrected age)"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Phase-I: 2 Year Follow-Up Safety and Efficacy Study of Pneumostem\u00ae in Premature Infants With Bronchopulmonary Dysplasia",
                              "Phase-I:Safety and Efficacy Evaluation of PNEUMOSTEM\u00ae Treatment in Premature Infants With Bronchopulmonary Dysplasia",
                              "Phase-II: Efficacy and Safety Evaluation of Pneumostem\u00ae Versus a Control Group for Treatment of BPD in Premature Infants"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://www.clinicaltrials.gov/ct2/show/record/NCT01632475?term=pneumostem&rank=1",
                              "http://www.clinicaltrials.gov/ct2/show/NCT01297205?term=pneumostem&rank=4",
                              "http://www.clinicaltrials.gov/ct2/show/NCT01828957?term=pneumostem&rank=2"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02023788"
                        ]
                  },
                  {
                        "Rank": 20,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Percentage of subjects who have moderate/severe BPD or are dead",
                              "Percentage of subjects by severity of BPD",
                              "Percentage of subjects in death due to lung disease",
                              "intubation duration",
                              "ventilation duration",
                              "continuous positive airway pressure (CPAP) treatment duration",
                              "treatment duration with supplemental oxygen",
                              "% of subjects treated with steroid for weaning ventilator",
                              "number of subjects with ROP with stage III or higher",
                              "number of subjects with retinopathy of prematurity that needs bevacizumab or laser therapy",
                              "percentile for body weight, height, and head circumference",
                              "days in hospitalization",
                              "changes in tracheal suction fluid examination"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Percentage of subjects who have moderate/severe BPD or are dead",
                              "Percentage of subjects by severity of BPD",
                              "Percentage of subjects in death due to lung disease",
                              "intubation duration",
                              "ventilation duration",
                              "continuous positive airway pressure (CPAP) treatment duration",
                              "treatment duration with supplemental oxygen",
                              "% of subjects treated with steroid for weaning ventilator",
                              "Retinopathy of prematurity (ROP) with stage III or higher",
                              "number of subjects with retinopathy of prematurity that needs bevacizumab or laser therapy",
                              "z-score",
                              "days in hospitalization",
                              "changes in tracheal suction fluid examination"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "36 weeks PMA",
                              "prenatal 28 days/36 weeks PMA",
                              "prenatal 28 days/36 weeks PMA and study end timepoint",
                              "up to 24 weeks",
                              "up to 24 weeks",
                              "up to 24 weeks",
                              "up to 24 weeks",
                              "up to 24 weeks",
                              "up to 24 weeks",
                              "up to 24 weeks",
                              "up to 24 weeks (visit 10)",
                              "up to 24 weeks",
                              "from screening to 7 days after IP administration (visit 5)"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03392467"
                        ]
                  },
                  {
                        "Rank": 21,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Rate of death until discharge or 40 weeks corrected gestational age, whichever comes first",
                              "Blood culture-proven sepsis\nPatent ductus arteriosus (treated medically or surgically)\nNecrotizing enterocolitis\nIsolated intestinal perforation\nRetinopathy of prematurity requiring treatment\nSevere intraventricular hemorrhage (\u2265 grade 3)\nCystic periventricular leukomalacia",
                              "Measures of gas exchange",
                              "Time to extubation\nDuration of mechanical ventilation\nDuration of non-invasive positive pressure respiratory support\nDuration of supplemental oxygen",
                              "This is a yes/no measure",
                              "Measured as mild, moderate, or severe",
                              "Measured according to the physiological definition of BPD (BPD at 36 weeks corrected age)",
                              "Targeted neonatal echocardiography to assess pulmonary hypertension using validated parameters",
                              "Markers of inflammation will be assessed in patient serum samples",
                              "Biomarkers of lung improvement will be assessed in patient tracheal aspirate samples",
                              "Successful recruitment and administration of cells to nine patients in 18 months",
                              "Proportion of potentially eligible patients that are successfully screened\nProportion of participants successfully screened who do not enroll (reason for failure to enroll will be recorded)",
                              "Median time from screening to enrollment\nMedian time from screening to cell administration",
                              "Proportion of patients that do not complete cell infusion\nProportion of patients enrolled that do not undergo scheduled follow-up",
                              "Assessment of cognitive, language, and motor development",
                              "Participant's overall health will be assessed through a questionnaire administered over the phone, once a year for 10 years",
                              "Characterize parental views of an animated MSC information video through brief semi-structured interviews"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Rate of Death",
                              "Occurrence of Other Severe Complications of Prematurity",
                              "FiO2 and Oxygen Index",
                              "Need for Ventilatory Support",
                              "Need for Postnatal Steroids",
                              "Incidence and Severity of BPD",
                              "Rate of Survival Without (moderate or severe) BPD",
                              "Changes in Pulmonary Hemodynamics",
                              "Biological Measure of Clinical Improvement",
                              "Biological Measure of Lung Improvement",
                              "Feasibility: Cell Administration",
                              "Feasibility: Recruitment Efficiency",
                              "Feasibility: Recruitment Timing",
                              "Feasibility: Participant Retainment",
                              "Bayley Scale of Infant and Toddler Development",
                              "Long-term Safety Follow-Up",
                              "Animated Information Video"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "From enrollment until discharge or 40 weeks corrected gestational age (whichever occurs first)",
                              "From enrollment until discharge or 40 weeks corrected gestational age (whichever occurs first)",
                              "From enrollment until discharge, 40 weeks corrected gestational age, or death (whichever occurs first)",
                              "From enrollment until discharge, 40 weeks corrected gestational age, or death (whichever occurs first)",
                              "From enrollment until discharge, 40 weeks corrected gestational age, or death (whichever occurs first)",
                              "From enrollment until discharge, 40 weeks corrected gestational age, or death (whichever occurs first)",
                              "From enrollment until 36 weeks corrected gestational age",
                              "At enrollment, 48 hours following uc-MSC injection, 28 days of life, and 36 weeks corrected gestational age",
                              "72-96 hours following uc-MSC injection",
                              "72-96 hours following uc-MSC injection",
                              "Day of life 7-21",
                              "Day of life 7-21",
                              "Day of life 7-21",
                              "From enrollment until follow-up at 18-24 months-of-age",
                              "18-24 months-of-age",
                              "Ten years following follow-up visit",
                              "Day of life 7-21"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04255147"
                        ]
                  }
            ]
      }
}